- Home
- Companies
- usa new jersey
- t standard polystyrene disposable cell
Show results for
Refine by
T Standard Polystyrene Disposable Cell Suppliers Serving Usa New Jersey
64 companies found
based inSan Diego, CALIFORNIA (USA)
Invivoscribe is a global leader in molecular diagnostics, providing a comprehensive range of standardized, CE-marked in vitro diagnostic products and companion diagnostics for hematology-oncology. The company's offerings include research use only ...
based inSALUGGIA, ITALY
We are global leader in the laboratory diagnostics market, specializing in the immunodiagnostics and molecular diagnostics segments. For over 50 years we have been dealing with diagnostics to help physicians and patients make better decisions in the ...
DiaSorin strives to improve health-care around the globe through the development of innovative diagnostic solutions that can lead to better patient outcomes and provide economic benefits to the healthcare system. Thanks to its team of dedicated ...
based inChuo-ku, JAPAN
Takeda is a patient-focused, values-based, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future to people worldwide. Our passion and pursuit of potentially life-changing treatments for patients are ...
Adaptate Biotherapeutics is focussed on therapeutic antibodies which harness the potential of patients’ own gamma delta T cells in situ. Gamma delta T cells play a critical role in immune surveillance, recognising malignant/transformed ...
based inParis, FRANCE
Enterome is pioneering the discovery and development of novel pharmaceuticals based on its unrivalled understanding of the interaction between the gut microbiome and the immune system – the Microbiome-Immunoinflammation Axis. Enterome is using this ...
OncoMimicsTM vaccines are a specific combination of bacterial peptides, derived from bacteria present in the gut microbiome, that closely mimic either overexpressed tumor-associated antigens (TAAs) or lineage-specific markers in solid and liquid ...
based inNotting Hill, AUSTRALIA
Cartherics is developing its novel “off-the-shelf” (allogeneic) immune therapy products for the treatment of cancer based on immune killer cells. The company is developing large-scale manufacture of these CAR-iNK cells for application in human ...
This technology arms the patient’s own T cells with CARs, which enable them to “seek and destroy” cancer ...
based inDallas, TEXAS (USA)
Lupagen is a privately held early stage biotech company developing first-in-class bedside enabled cell & gene therapies (CAR-T cell, gene editing and immunotherapy products) based on their patent-pending bedside point-of-care C and GT production and ...
based inNew York, NEW YORK (USA)
IN8bio was founded in 2016 with the mission of developing novel therapies to address cancer. The company is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T-cell product ...
INB-300, our DeltEx DRI CAR-T, is a preclinical product candidate combining our expertise in gamma-delta T cells, our DRI technology and a novel CAR-directed against the Cholotoxin peptide. Chlorotoxin binds to GBM tumor cells and has been ...
based inFlorham Park, NEW JERSEY (USA)
Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and ...
Chimeric Antigen Receptor T cells (CAR-T) are genetically engineered T cells that are modified to express an artificial T cell receptor on their surface that binds and targets cancer proteins in an HLA-independent ...
based inBoston, MASSACHUSETTS (USA)
At PathAI, we’re dedicated to improving patient outcomes with reliable AI-Powered technology and meaningful collaboration with biopharma, laboratories, and clinicians — aiming to provide patients with access to accurate diagnoses and effective ...
based inPhiladelphia, PENNSYLVANIA (USA)
Context is dedicated to developing the next generation of therapies to treat solid tumors, with a primary focus on female cancers. Female cancers include breast, ovarian, and endometrial cancer. To target these cancers, we are advancing bispecific ...
There is growing interest in applying antibody modalities including bispecifics, antibody-drug conjugates, and CART to solid tumors. However, identifying appropriate tumor-specific targets that avoid adverse effects in healthy tissue has been ...
based inWilmington, NORTH CAROLINA (USA)
AccuGenomics manufactures innovative multiplexed spike-in QC standards (SNAQ-SEQ) that enable a host of highly sensitive next generation sequencing applications. SNAQ-SEQ internal standards improve the accuracy and performance of NGS-based assays. ...
based inCleveland, OHIO (USA)
Cellular Technology Limited (CTL) is a biotechnology company headquartered in Shaker Heights, a suburb of Cleveland, Ohio, with locations and distributors worldwide. We presently have around 180 full-time employees. Our company is family owned and ...
based inMilano, ITALY
We are a clinical-stage biotechnology company pioneering the treatment of cancers with a technology platform that allows the direct delivery of immunotherapeutic payloads within the tumor microenvironment. Intrinsic resistance significantly reduces ...
based inSan Diego, CALIFORNIA (USA)
We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19. Cancer is genetically diverse, highly adaptive, constantly mutating and virtually invisible to ...
Sorrento utilizes a proprietary knock-out knock-in (KOKI) technology to modify normal healthy donor derived T cells to genetically engineer them to express the dimeric antigen receptor into T-cell receptor (TCR) alpha chain constant region ...
based inCambridge, MASSACHUSETTS (USA)
The human body is an ecosystem. Trillions of microbes call us home. They form the human microbiome, which performs critical functions that preserve our health including modulating our immune system and providing colonization resistance against ...
From Ruslan Medzhitov's discovery of toll-like receptors (TLRs) as the key immune system receptors that detect infection, which spawned the field of innate immunity, to Dan Littman's efforts to identify and clone CD4 and CD8, molecules on the ...
based inHillsborough, NEW JERSEY (USA)
LifeTein, located in Somerset, New Jersey, was founded in 2008 with a simple vision: understanding life sciences one protein at a time. This philosophy has formed the foundation of every peptide, protein, antibody, gene, and chemical project that we ...
based inUtrecht, NETHERLANDS
At LAVA, we are focused on applying our expertise in gamma-delta T cell engagers. We are building a pipeline of gamma-delta bsTCEs that have applications in both solid and hematologic malignancies. Our lead program, LAVA-051, targets the tumor ...
Our lead program, LAVA-051, is a unique, humanized gamma-delta bsTCE targeting CD1d-expressing tumors, including multiple myeloma, chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML). We have achieved preclinical proof-of-concept ...
based inFreiburg, GERMANY
Sartorius CellGenix is a leading global supplier of high quality raw and ancillary materials for the expanding market of cell and gene therapy and regenerative medicine. We develop, manufacture and market human cytokines, growth factors, and other ...
CellGenix Recombinant Human Flt-3L reliably supports the proliferation of hematopoietic stem cells (HSCs). CellGenix® rh Flt-3L is produced in our dedicated animal-free GMP facility ensuring maximum safety for optimal use in ATMP ...
based inPlanegg, GERMANY
TQ Therapeutics GmbH is pioneering a novel approach to cell and gene therapy with its TQx platform, which transforms the production of cellular therapies into a rapid, automated process that occurs at the patient's side. This method leverages ...
based inSeattle, WASHINGTON (USA)
We believe we are entering a new era of medicine. The ability to modify genes and use cells as medicines provides new tools to meaningfully change the outcome of many human diseases. Early pioneers have made good progress, but most of what we can ...
Oncology: Non-Hodgkin lymphoma (NHL), Acute lymphoblastic leukemia (ALL), Chronic lymphocytic leukemia ...